People | July 07, 2025
Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
A triple-action Formula for comprehensive respiratory relief
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Subscribe To Our Newsletter & Stay Updated
